Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial-Reference-Cited by-同舟云学术

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial

Published:2020-10 Issue:10257 Volume:396 Page:1079-1089
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kim Hyo-Soo,Kang Jeehoon,Hwang Doyeon,Han Jung-Kyu,Yang Han-Mo,Kang Hyun-Jae,Koo Bon-Kwon,Rhew Jay Young,Chun Kook-Jin,Lim Young-Hyo,Bong Jung Min,Bae Jang-Whan,Lee Bong Ki,Park Kyung Woo

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

3. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial;Park;Circulation,2019

4. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study;Cuisset;Eur Heart J,2017

5. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry;De Luca;EuroIntervention,2017

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic Therapy in Acute Coronary Syndrome;Interventional Cardiology Clinics;2024-10

2. Efficacy and safety of Tongxin formula after stent implantation for acute coronary syndrome: A multicenter, double-blind, placebo-controlled randomized trial;EXPLORE;2024-09

3. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial;European Heart Journal - Cardiovascular Pharmacotherapy;2024-07-18

4. Optimal antiplatelet therapy in patients with acute coronary syndromes — a still unfulfilled need?;Cardiology Journal;2024-06-28

5. Review of the Ticagrelor Trials Evidence Base;Journal of the American Heart Association;2024-06-04